Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.

PLoS One · 2015 · PMC4319932 · PMID 25658425

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Rats expressing α-Syn and treated with the anti-α-Syn AB1 or AB2 antibody showed a trend towards amelioration of this behavioral deficit as they were not significantly different from the control AAV-GFP treatment group at any time point.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.